Trial Profile
An Open-label, Multicenter, Expanded Access Study of INC424 for Patients With Primary Myelofibrosis (PMF) or Post Polycythemia Myelofibrosis (PPV MF) or Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Jan 2024
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
- Focus Adverse reactions; Expanded access
- Acronyms JUMP
- Sponsors Novartis; Novartis Pharmaceuticals
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 01 Oct 2021 Results of post-hoc analysis assessing the safety and efficacy of ruxolitinib in patients stratified by Dynamic International Prognostic Scoring System (DIPSS) risk categories published in the Hematological Oncology
- 17 Jun 2021 Results of post-hoc analysis assessing impact of Bone marrow fibrosis grade on response and outcome in patients with primary myelofibrosis presented at the 26th Congress of the European Haematology Association